Evidence map›Paper›PMID 34104649›Full record

ArticleBioMed research international2021

Interpreting the Molecular Mechanisms of Yinchenhao Decoction on Hepatocellular Carcinoma through Absorbed Components Based on Network Pharmacology.

Jijia Sun, Tao Han, Tao Yang, Yunhui Chen, Jihan Huang

Abstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Recent therapeutics in hepatocellular carcinoma.American journal of cancer research · 2023
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jijia SunCenter for Drug Clinical Research, Shanghai Traditional Chinese Medicine Health Service Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0003-3754-4063
Tao HanCenter for Drug Clinical Research, Shanghai Traditional Chinese Medicine Health Service Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Tao YangCenter for Drug Clinical Research, Shanghai Traditional Chinese Medicine Health Service Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0003-2355-1270
Yunhui ChenCollege of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.ORCID https://orcid.org/0000-0002-3555-8018
Jihan HuangCenter for Drug Clinical Research, Shanghai Traditional Chinese Medicine Health Service Collaborative Innovation Center, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.ORCID https://orcid.org/0000-0002-2176-737X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To investigate the mechanisms through which Yinchenhao decoction (YCHD) inhibits hepatocellular carcinoma (HCC), we analyzed YCHD ingredients absorbed into the bloodstream by using network pharmacology. We conducted a weighted gene coexpression network analysis on gene expression data collected from the Gene Expression Omnibus and The Cancer Genome Atlas databases to derive an HCC gene set; moreover, we used four online prediction system databases to predict the potential targets of YCHD ingredients absorbed into the bloodstream. We discovered that YCHD directly interfered with 17 HCC-related disease targets. Subsequent gene ontology enrichment analyses of these 17 disease targets revealed that YCHD exhibited effects through 17 biological processes, 7 molecular functions, and 9 cellular components. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses indicated 14 pathways through which YCHD inhibits HCC. We observed similar trends in how the 17 small molecules interfered with the key target set. We surmised that YCHD inhibits HCC by regulating inflammatory and metabolic pathways. Network pharmacological analysis of YCHD ingredients absorbed into the bloodstream may provide new insights and serve as a new method for discovering the molecular mechanisms through which YCHD inhibits HCC.

Indexed as

Carcinoma, HepatocellularDrugs, Chinese HerbalGene Expression RegulationGene OntologyHumansInflammationLiver NeoplasmsMetabolic Networks and PathwaysSmall Molecule LibrariesDrugs, Chinese HerbalSmall Molecule Librariesyinchenhao

Identifiers

PMID34104649
PMCPMC8159653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.